Submit NDA for ADX-2191
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Aug 2022
- Due
- 31 Dec 2022
- Delivered
- Q4 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Pending discussion with the FDA, an NDA submission is planned for the second half of 2022.”
What we found
Evidence strength A What the grades mean
The company successfully submitted the New Drug Application (NDA) for ADX-2191 in the fourth quarter of 2022, meeting its commitment to submit the application during the second half of 2022.
-
A Aldeyra Therapeutics, Inc. 10-K filed 2023-03-09
“we submitted an NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma in the fourth quarter of 2022.” ✓ confirmed on the page
Market reaction: the shares moved -1.4% against the S&P 500 over the three sessions around the disclosure (8 Mar 2023 to 13 Mar 2023). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- NDA submission for ADX-2191
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: Pending discussion with the FDA
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-ALDX-003475 · Corrections policy